LOGIN  |  REGISTER
Chimerix

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference

January 05, 2023 | Last Trade: US$2.99 0.14 4.91

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 p.m. PT in San Francisco, CA.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:   

Michelle LaSpaluto
919 972-7115
This email address is being protected from spambots. You need JavaScript enabled to view it.

Will O’Connor
Stern Investor Relations
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.

Nick Lamplough / Dan Moore / Tanner Kaufman
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Stock Quote

BUY $CMRX

Buy $CMRX on Charles Schwab

Buy $CMRX on ETrade

Buy $CMRX on Public.com

Buy $CMRX on Fidelity

Buy $CMRX on  Robinhood

Buy $CMRX on Webull

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE
Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB